STJ
St. Jude Medical, Inc.NYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Yesterday, 4:04 PM
    • St. Jude Medical (NYSE:STJ) declares $0.31/share quarterly dividend, in line with previous.
    • Forward yield 1.54%
    • Payable Jan. 31; for shareholders of record Jan. 13; ex-div Jan. 11.
    | Yesterday, 4:04 PM
  • Thu, Dec. 8, 10:16 AM
    • St. Jude Medical (STJ -0.5%) announces that its Proclaim Elite Spinal Cord Stimulation (SCS) System is now CE Mark'd (with conditions) for use is patients undergoing full-body magnetic resonance imaging (MRI). In 2015, it was approved only for MRIs of the head and extremities.
    • The full-body MRI claim was also recently approved in the U.S.
    | Thu, Dec. 8, 10:16 AM | 1 Comment
  • Wed, Nov. 16, 4:14 PM
    • Preliminary results from the MOMENTUM 3 U.S. IDE study assessing St. Jude Medical's (NYSE:STJ) HeartMate 3 Left Ventricular Assist System (LVAS) in patients with Class IIIB (marked limitation in activity) or IV (severely limited in activity) heart failure showed a significant treatment benefit. The data were presented at the American Heart Association (AHA) Scientific Sessions in New Orleans, LA.
    • MOMENTUM 3 is an unblinded randomized prospective study involving more than 1,000 patients with left ventricular heart failure. The data presented at AHA were gathered at the six-month follow-up of the first 294 patients enrolled.
    • Patients receiving the HeartMate 3 LVAS experienced an 86.2% survival rate with freedom from disabling stroke and reoperation to repair or replace the device. There were no pump thrombosis events reported at month 6. The incidence rates of other adverse events were similar with historical rates observed with the product.
    • HeartMate 3 was CE Mark'd in December 2015. St. Jude acquired the rights via its acquisition of Thoratec in October 2015.
    | Wed, Nov. 16, 4:14 PM
  • Fri, Oct. 28, 3:51 PM
    • The FDA approves St. Jude Medical's (STJ -1.3%) AMPLATZER PFO Occluder to help reduce the risk of recurrent ischemic stroke in patients with a heart defect called a patent foramen ovale or PFO.
    • A PFO is a hole in the wall between the left and right atria. It is present in all human fetuses and it allows blood to bypass the fetal lungs which cannot work until they are exposed to air. Once a baby is born, the foramen ovale closes and is completely sealed in several months in ~75% of people. In the others it remains open although the leaking blood is not a problem for the majority with the defect. It can be a serious issue, though, when a blood clot is involved because the clot can pass from the right side of the heart to the left where it can travel into the brain and cause a stroke.
    • The AMPLATZER PFO Occluder is implanted close to the hole between the atria using a catheter. It has been available in the U.S. under a Humanitarian Device Exemption (HDE) since 2006 but was voluntarily withdrawn by the company after the agency determined that the target population for the device was greater than 4,000 thereby no longer qualifying it for HDE status.
    | Fri, Oct. 28, 3:51 PM
  • Wed, Oct. 26, 5:01 PM
    • As expected, St. Jude Medical (NYSE:STJ) shareholders overwhelmingly voted in favor of merging with Abbott (NYSE:ABT) at its Annual Meeting. About 99% of the votes cast, representing ~74% of St. Jude's outstanding stock, backed the $25B deal. The transaction should close by year end.
    | Wed, Oct. 26, 5:01 PM
  • Wed, Oct. 19, 9:16 AM
    • Despite being sued by St. Jude Medical (NYSE:STJ) alleging "false statements, false advertising, conspiracy and manipulation of the financial markets" related to the security of its implanted devices, short seller Muddy Waters fans the flames with a new video that reportedly shows how to reverse engineer the company's Merlin equipment allowing a hacker to manipulate certain commands which could turn the implanted cardiac device off completely or deliver an unnecessary shock to the heart.
    • Predictably, St. Jude says it stands behind the security and safety of its devices and criticizes Muddy for its "irresponsible release of information that is intended for financial gain." Nevertheless, it has created a cybersecurity medical advisory board and will continue to work with researchers to ensure that it has a thorough understanding of the cyber risks and potential vulnerabilities related to its products.
    • The company is in the midst of being acquired by Abbott (NYSE:ABT) for $25B.
    • Shares are down 2% premarket on increased volume.
    | Wed, Oct. 19, 9:16 AM | 3 Comments
  • Wed, Oct. 19, 7:57 AM
    • St. Jude Medical (STJ +2.3%) Q3 results: Revenues: $1,499M (+11.9%); Total U.S. Sales: $783M (+11.1%); Total International Sales: $716M (+12.9%); Operating Income: $286M (-2.7%); Net Income: $212M (-1.4%); EPS: $0.73 (-2.7%); Non-GAAP EPS: $0.99 (+2.1%); Quick Assets: $394M (-40.9%).
    • Q4 and FY16 Guidance: Due to the planned merger with Abbott, St. Jude Medical is withdrawing financial guidance for the fiscal year 2016.
    | Wed, Oct. 19, 7:57 AM
  • Wed, Oct. 19, 7:16 AM
    • St. Jude Medical (NYSE:STJ): Q3 EPS of $0.99 misses by $0.02.
    • Revenue of $1.5B (+11.9% Y/Y) in-line.
    • Shares -0.05% PM.
    • Press Release
    | Wed, Oct. 19, 7:16 AM
  • Tue, Oct. 18, 5:30 PM
    | Tue, Oct. 18, 5:30 PM | 7 Comments
  • Tue, Oct. 18, 8:16 AM
    • Abbott (NYSE:ABT) and St. Jude Medical (NYSE:STJ) have agreed in principle to sell certain products to Terumo (OTCPK:TRUMF)(OTCPK:TRUMY) for $1.12B in cash. The transaction, contingent on the successful completion of Abbott's $25B acquisition of St. Jude, includes St. Jude's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath.
    • Abbott will retain its vascular closure products, including the Perclose ProGlide Suture-Mediated Closure System, StarClose SE Vascular Closure System and Prostar XL Percutaneous Vascular Surgical System.
    • Abbott adds that its expects to mitigate any impact on non-GAAP earnings related to the sale of the assets.
    | Tue, Oct. 18, 8:16 AM | 2 Comments
  • Tue, Oct. 11, 12:15 PM
    • Although the market's down day is certainly a factor, Abbott Laboratories (ABT -4.3%) appears to be suffering from St. Jude Medical's (STJ -3.4%) problem with premature battery depletion in some of its implantable devices, an issue that the company admits has affected 0.2% (n=841/400,000) of its devices made through May of last year. Two deaths have been attributed to the issue, caused by lithium clusters, so far.
    • In April, Abbott announced that it would acquire St. Jude for $25B.
    • Previously: Some St. Jude heart devices at risk of premature battery depletion, two deaths reported; shares down 6% premarket (Oct. 11)
    | Tue, Oct. 11, 12:15 PM | 7 Comments
  • Tue, Oct. 11, 11:57 AM
    • The market's down day notwithstanding, Medtronic (MDT -2.3%) is feeling St. Jude Medical's (STJ -3.6%) pain this morning as investors perceive that it may have the same lithium cluster problem with its implantable devices. St. Jude was down almost 7% earlier today after news hit that some of its devices may be at risk of premature battery depletion due to the problem. St. Jude says it is rare, occurring in 0.2% of its devices manufactured through May of last year (841 out of 400K).
    • Previously: Some St. Jude heart devices at risk of premature battery depletion, two deaths reported; shares down 6% premarket (Oct. 11)
    | Tue, Oct. 11, 11:57 AM
  • Tue, Oct. 11, 7:52 AM
    • St. Jude Medical (NYSE:STJ) eases 6% premarket on increased volume in response to the news that some of its implanted heart devices are at risk of premature battery depletion due to the formation of lithium clusters which can form after the device delivers electricity to the heart. The situation makes the device unable to deliver doses of electricity when needed. Two patient deaths have been attributed to the problem thus far.
    • The issue surfaced yesterday evening when short seller Muddy Waters tweeted a copy of a physician advisory sent by the company. It advises doctors to immediately replace devices with damaged batteries but not those that are operating normally.
    • It is a rare problem. St. Jude says only 841 cardioverter defibrillators out of almost 400,000 manufactured through May of last year have been identified with lithium clusters.
    | Tue, Oct. 11, 7:52 AM | 2 Comments
  • Thu, Oct. 6, 10:26 AM
    • St. Jude Medical (STJ +0.3%) announces the U.S. commercial launch and first implant of its Infinity Deep Brain Stimulation (DBS) system, indicated for the treatment of Parkinson's disease and essential tremor, two of the most common movement disorders.
    • Infinity is the only DBS system that operates on a wireless iOS software platform. It can be programmed with an iPad mini mobile device by the neurologist while the patient can personalize therapy via an iPod touch mobile digital device patient controller.
    | Thu, Oct. 6, 10:26 AM
  • Wed, Oct. 5, 9:02 AM
    • St. Jude Medical (NYSE:STJ) announces the full market release of its EnSite Precision cardiac mapping system and new Sensor Enable tools in Europe, now installed in more than 100 sites there. The product was CE Mark'd in January.
    • Efforts to gain regulatory clearance in the U.S. are ongoing.
    | Wed, Oct. 5, 9:02 AM
  • Tue, Oct. 4, 10:36 AM
    • The FDA approves St. Jude Medical's (STJ) newest spinal cord stimulation (SCS) option, BurstDR, for the relief of chronic pain. The company says it is superior to other SCS designs because its intermittent "burst" pulses mimic the body's natural nerve impulse patterns.
    • Patients newly implanted with St. Jude's Proclaim Elite and Prodigy MRI SCS systems will have immediate access to the new therapy. Patients previously implanted with the upgradeable Protege and Proclaim SCS systems will soon be able to upgrade to BurstDR stimulation without additional surgery.
    | Tue, Oct. 4, 10:36 AM